LENZ Therapeutics reported third quarter 2026 total revenue of $3.4 million, missing the consensus estimate of $4.2 million. While the company achieved sequential growth in product sales, it announced a massive strategic reorganization including a 75% reduction in force and the resignation of its CEO.
Key Highlights
- VIZZ product sales reached $2.6 million for the quarter, reflecting 50% sequential growth over the prior quarter supported by 38,000 paid prescriptions.
- Massive restructuring involves reducing headcount by 75% to approximately 40 employees to lower projected 2027 operating expenses by over 50%.
- Management transition confirmed as CEO Eef Schimmelpennink will resign effective December 1, 2026, with CFO Daniel Chevallard serving as Interim CEO.
- Telehealth adoption surged during the period, with the July 2026 platform launch contributing more than 50% of the incremental prescriptions gained over the second quarter.